glp 1 gastroparesis Diabetic and Glycaemic Control | Current Diabetes Reports Managing patients taking glucagon-like peptide-1
Description
(2019) showed that diabetes could damage the integrity of the Neurovascular unit (NVU) in the hippocampus and reduce BDNF levels in endothelial cells and HT22 hippocampal neurons
For example, a 2025 study showed an average loss of 7.9 to 12 lbs in PCOS patients
The trial demonstrated a significant reduction of 25% in the primary composite outcome of cardiovascular death and first HFH (19.4% versus 24.7% [HR 0.75
There are also side effects to taking GLP-1s, most of which are related to gastrointestinal issues
